The panelist discusses how early detection of recurrent Clostridioides difficile infections is critical in clinical practice because these infections can rapidly escalate patient morbidity and ...

Paul Feuerstadt, MD, FACG, AGAF, discusses how testing for Clostridioides difficile is recommended for hospitalized patients or outpatients with new-onset, unexplained diarrhea who have risk factors ...

Results from a Phase 1b/2 trial suggest that an investigational microbiome-based, oral therapeutic drug is effective for the treatment of recurrent C. difficile infection. In a paper published online ...

Acurx's Program in the Broader CDI Patient Population is Ready to Advance toPhase 3 International Clinical Trials Acurx previously announced that it had received positive regulatory guidance from the ...

The recent approval of the first oral fecal-derived microbiota therapy to prevent the recurrence of Clostridioides difficile (C. diff) infection in patients was welcome news for physicians who've ...

University of Wisconsin–Madison–led researchers report lower yet statistically non-significant recurrence of Clostridioides difficile (C. diff) among adults given low-dose oral vancomycin during ...

In a recent study published in JAMA Network Open, a team of researchers investigated the tolerability and safety of a microbiome therapy called SER-109 to treat recurrent infections of Clostridioides ...

Please provide your email address to receive an email when new articles are posted on . Allegretti presented data at Digestive Disease Week on safety outcomes and concomitant medication changes after ...

— Greg Vigna, M.D., J.D. SANTA BARBARA, CA, UNITED STATES, August 3, 2023/EINPresswire.com/ -- “Prolonged IV antibiotics are necessary for the treatment of Grade ...

Please provide your email address to receive an email when new articles are posted on . Treatment-emergent adverse events occurred in 66.4% of patients who received Rebyota vs. 60.2% on placebo. Most ...